Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06612775 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy

Name: A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy — clinical trial record (NCT06612775)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorShanghai Zhimeng Biopharma, Inc.

Started2024-08-14

View on ClinicalTrials.gov ↗

Trial flagged as At Risk

Primary completion moved at least 12 months later Aug 2026 → Sep 2027

See other at-risk trials from Shanghai Zhimeng Biopharma, Inc.

Amendment history

2026-09-23

Recruitment opened

Primary completion pushed: 2026-08 → 2027-09

Completion pushed: 2026-09 → 2027-11

Shanghai Zhimeng Biopharma, Inc.

4 trials monitored

See 1 trial at risk

Epilepsy

723 trials monitored

See 41 trials at risk

CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy.

Trial Details

NCT Number	NCT06612775
Lead Sponsor	Shanghai Zhimeng Biopharma, Inc.
Conditions	Focal Epilepsy
Enrollment	180 participants
Start Date	2024-08-14
Primary Completion	2027-09 (estimated)
Study Completion	2027-11 (estimated)
Updated on ClinicalTrials.gov	2026-09-22